Developer docs
API playgroundTry for free, no card

Search company profiles

AiVF

Full company profile

uuid0000y5c

Namestring
AiVF
Legal namestring
AIVF Ltd.
Websiteurl
aivf.co
Company typeenum
Private
Founded yearint
2018
Descriptiontext

AIVF Ltd. is an Israeli medical technology company founded in 2018 by clinical embryologist Daniella Gilboa (CEO) and reproductive medicine specialist Prof. Daniel Seidman (CMO), headquartered in Tel Aviv. The company develops an AI-powered platform for in vitro fertilization (IVF), centered on the EMA (Embryology Management Assistant) system, which applies deep learning and computer vision to time-lapse embryo images to predict clinical pregnancy probability and assist embryologists in embryo selection. The platform is modular, including AIVF Day-3 (early-stage evaluation), AIVF Day-5 (blastocyst evaluation), AIVF Genetics (non-invasive probabilistic euploidy scoring that substitutes for invasive PGT-A biopsy), Advanced IVF Analytics (EMR-connected KPI and data mining tools), and an Integrated Messaging Dashboard for care team coordination. AIVF also operates the ART Compass subsidiary for IVF lab management, and offers a patient-facing mobile app.

The company sells to enterprise IVF clinics and fertility centers via direct field sales on an annual subscription basis, with deployments integrated into existing clinic workflows through connectors to time-lapse incubators (Embryoscope, Geri via Genea Biomedx) and EMR systems. It holds CE Mark, ISO 13485, ISO 27001, ISO 27799, and is HIPAA and GDPR compliant; in the US, the AI is currently limited to investigational use pending FDA clearance. As of 2023, AIVF had raised approximately $35 million in total funding, including a $25 million Series A led by Insight Partners in June 2022, and operates across Israel, the United States, the United Kingdom, France, Ireland, Greece, and Brazil with reference customers including Perfetto Clinic, First IVF, Embryolab, and the American Hospital of Paris.

Short descriptiontext

AIVF Ltd. is an Israeli medical technology company founded in 2018 that builds an AI-powered IVF platform (EMA) using deep learning on time-lapse embryo images to predict pregnancy probability and assist embryo selection, sold via enterprise SaaS subscriptions to IVF clinics and fertility centers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI embryo evaluation, IVF clinical software, fertility clinic analytics, embryology management platform, reproductive medicine AI
Industry1 code
PRIMARYBPAEAHAF
AI/ML Engineering & Model Development Services
NAICS code3 codes
  • Software Publishers5132
  • Custom Computer Programming Services541511
  • Computer Systems Design Services541512
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Computer Programming Services7371
  • Services-Computer Integrated Systems Design7373
Product category
Clinical decision-support software for IVF / reproductive medicine
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Subscription
TypeSubscription Recurring
Description

AiVF operates on a B2B SaaS model providing IVF clinics with access to its AI-powered EMA platform. Clinics pay subscription fees for embryo evaluation, analytics, and communication tools.

bebeez.it
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Enterprise pricing for IVF clinics
ModelSubscriptionBilling cadenceAnnual
Notes

No public pricing available. Contact sales for quote.

aivf.co
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1AIVF Day-3
Description

Early-stage embryo evaluation for clinical pregnancy prediction

aivf.co
+4 more records
Core offering1 text field

AIVF develops and sells the EMA (Embryology Management Assistant) platform — an AI-powered clinical decision-support SaaS for IVF clinics that performs automated, deep-learning-based embryo evaluation (Day-3 and Day-5), non-invasive euploidy prediction via AIVF Genetics, and clinic-wide analytics and messaging, integrating with time-lapse incubators (Embryoscope, Geri) and EMR systems. The company also offers ART Compass (lab management) and a patient mobile app as adjacent products to its core IVF clinic software.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 70% probability of success for embryos with high AIVF score
+4 more records
Product overview1 text field

AIVF offers a modular AI-powered IVF platform centered on the EMA (Embryology Management Assistant) system with interconnected modules for embryo evaluation, genetics analysis, analytics, and communication. The core EMA Platform provides Day-3 and Day-5 AI embryo evaluation powered by computer vision and predictive analytics. AIVF Genetics module adds non-invasive euploidy screening. The platform includes Advanced IVF Analytics for clinic data insights and an Integrated Messaging Dashboard for care team coordination. AIVF also provides a patient-facing Mobile App and operates ART Compass subsidiary for lab management. All modules share data through EMR connectivity for a unified clinic workflow.

Product and service4 records
1EMA Platform (Embryology Management Assistant)
CategoryClinical decision-support software for IVF
Description

End-to-end AI-powered embryo evaluation SaaS platform that connects the entire IVF care team through automated embryo grading, analytics, and communication tools, integrating with time-lapse incubators (Embryoscope, Geri) and EMR systems. Designed for IVF clinics and fertility centers seeking to standardize embryo selection, reduce evaluation time, and improve pregnancy rates.

2AIVF Genetics
CategoryClinical decision-support software for IVF
Description

Non-invasive AI tool that provides probabilistic euploidy estimates (0-99 score) for embryos using time-lapse imaging, integrating maternal age, embryo morphology scores, morphokinetic parameters, and Embryo Resilience data to support genetic-quality assessment without invasive PGT-A biopsy. Targeted at IVF clinics and reproductive medicine labs.

3ART Compass
CategoryIVF lab management software
Description

Wholly-owned AIVF subsidiary product offering IVF lab management tools and a clinic operating system for quality assurance and laboratory workflow support, used by fertility clinics and embryology labs.

4AIVF Mobile App
CategoryPatient engagement mobile app
Description

Patient-facing mobile application that provides access to personal fertility health data processed by the clinic, remote journey monitoring, and scheduling features for patients undergoing IVF treatment.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

The American Hospital of Paris uses AIVF technology to analyze embryo development data, aiming to halve the number of IVF cycles needed to achieve pregnancy with 70% probability that recommended embryos will not have genetic abnormalities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-18
Description

Strategic partnership announced in May 2023 to integrate AIVF's AI-powered EMA platform with Genea Biomedx's Geri time-lapse incubator, expanding support for AI-powered embryo evaluation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Genea Biomedx manufactures Geri time-lapse incubators and is AIVF's integration partner; as a major incubator OEM with R&D resources it represents both a channel and a potential competitor.

TypeDirect peer
Description

Alife Health applies AI to IVF clinical decision support and embryo selection, directly competing with AIVF's EMA platform for the same fertility clinic customers with similar AI-on-time-lapse-imaging workflows.

3Fairtility
TypeDirect peer
Description

Fairtility offers AI-based embryo assessment and decision-support tools for IVF clinics, competing head-to-head with AIVF in automating embryo grading and ranking using time-lapse incubator data.

4Embryonics
TypeEmerging player
Description

Embryonics develops AI-powered embryo viability prediction for IVF, an emerging niche player overlapping with AIVF's Day-3/Day-5 evaluation offerings.

TypeBroad incumbent
Description

Vitrolife is a global IVF media, device and genomics supplier whose Embryoscope time-lapse incubator platform is integrated with AIVF; as a broad incumbent it could build or bundle competing AI embryo scoring.

TypeBroad incumbent
Description

CooperSurgical is a large incumbent in fertility and reproductive medicine spanning devices, genomics (PGT-A) and lab services, with overlapping AI-adjacent capabilities and the distribution to challenge AIVF in clinics.

TypeBroad incumbent
Description

FUJIFILM Irvine Scientific is a leading supplier of IVF media, devices and digital tools to fertility clinics, representing a broad incumbent whose scale and customer relationships compete with AIVF's clinic OS.

TypeBroad incumbent
Description

Hamilton Thorne provides ART/IVF instruments and clinical devices globally; its installed base of laser systems and imaging hardware gives it a platform adjacent to AIVF's AI evaluation layer.

TypeDirect peer
Description

Univfy provides AI-based IVF success prediction and patient counseling tools to fertility clinics, directly competing with AIVF's analytics and decision-support positioning.

TypeOthers
Description

Progyny is a leading fertility benefits management platform that influences which clinics and tools patients use; it is an adjacent ecosystem player whose provider selection decisions can drive or constrain AIVF clinic adoption.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AiVF

Clinical decision-support software for IVF / reproductive medicineaivf.co

AIVF Ltd. is an Israeli medical technology company founded in 2018 that builds an AI-powered IVF platform (EMA) using deep learning on time-lapse embryo images to predict pregnancy probability and assist embryo selection, sold via enterprise SaaS subscriptions to IVF clinics and fertility centers globally.

What AiVF does

AIVF Ltd. is an Israeli medical technology company founded in 2018 by clinical embryologist Daniella Gilboa (CEO) and reproductive medicine specialist Prof. Daniel Seidman (CMO), headquartered in Tel Aviv. The company develops an AI-powered platform for in vitro fertilization (IVF), centered on the EMA (Embryology Management Assistant) system, which applies deep learning and computer vision to time-lapse embryo images to predict clinical pregnancy probability and assist embryologists in embryo selection. The platform is modular, including AIVF Day-3 (early-stage evaluation), AIVF Day-5 (blastocyst evaluation), AIVF Genetics (non-invasive probabilistic euploidy scoring that substitutes for invasive PGT-A biopsy), Advanced IVF Analytics (EMR-connected KPI and data mining tools), and an Integrated Messaging Dashboard for care team coordination. AIVF also operates the ART Compass subsidiary for IVF lab management, and offers a patient-facing mobile app.

The company sells to enterprise IVF clinics and fertility centers via direct field sales on an annual subscription basis, with deployments integrated into existing clinic workflows through connectors to time-lapse incubators (Embryoscope, Geri via Genea Biomedx) and EMR systems. It holds CE Mark, ISO 13485, ISO 27001, ISO 27799, and is HIPAA and GDPR compliant; in the US, the AI is currently limited to investigational use pending FDA clearance. As of 2023, AIVF had raised approximately $35 million in total funding, including a $25 million Series A led by Insight Partners in June 2022, and operates across Israel, the United States, the United Kingdom, France, Ireland, Greece, and Brazil with reference customers including Perfetto Clinic, First IVF, Embryolab, and the American Hospital of Paris.

AiVF firmographics

Firmographics
Name
AiVF
Legal name
AIVF Ltd.
Website
https://aivf.co
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
AIVF Ltd. is an Israeli medical technology company founded in 2018 that builds an AI-powered IVF platform (EMA) using deep learning on time-lapse embryo images to predict pregnancy probability and assist embryo selection, sold via enterprise SaaS subscriptions to IVF clinics and fertility centers globally.
Ownership category
akta.pro rank

AiVF industry classification

Industry
Product category
Clinical decision-support software for IVF / reproductive medicine
NAICS
Software Publishers (5132), Custom Computer Programming Services (541511), Computer Systems Design Services (541512)
SIC
Services-Prepackaged Software (7372), Services-Computer Programming Services (7371), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYBPAEAHAF
AI/ML Engineering & Model Development Services

Keywords

  • AI embryo evaluation
  • IVF clinical software
  • Fertility clinic analytics
  • Embryology management platform
  • Reproductive medicine AI

Where AiVF is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

AiVF business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. SaaS Platform Subscription: AiVF operates on a B2B SaaS model providing IVF clinics with access to its AI-powered EMA platform. Clinics pay subscription fees for embryo evaluation, analytics, and communication tools.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise pricing for IVF clinics

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

AiVF product offering

Product offering

Core offering

AIVF develops and sells the EMA (Embryology Management Assistant) platform — an AI-powered clinical decision-support SaaS for IVF clinics that performs automated, deep-learning-based embryo evaluation (Day-3 and Day-5), non-invasive euploidy prediction via AIVF Genetics, and clinic-wide analytics and messaging, integrating with time-lapse incubators (Embryoscope, Geri) and EMR systems. The company also offers ART Compass (lab management) and a patient mobile app as adjacent products to its core IVF clinic software.

Product overview

AIVF offers a modular AI-powered IVF platform centered on the EMA (Embryology Management Assistant) system with interconnected modules for embryo evaluation, genetics analysis, analytics, and communication. The core EMA Platform provides Day-3 and Day-5 AI embryo evaluation powered by computer vision and predictive analytics. AIVF Genetics module adds non-invasive euploidy screening. The platform includes Advanced IVF Analytics for clinic data insights and an Integrated Messaging Dashboard for care team coordination. AIVF also provides a patient-facing Mobile App and operates ART Compass subsidiary for lab management. All modules share data through EMR connectivity for a unified clinic workflow.

Differentiator

Problem solved

Functional benefit

Brands

  • AIVF Day-3: Early-stage embryo evaluation for clinical pregnancy prediction
  • AIVF Day-5
  • AIVF Genetics
  • ART Compass
  • FertilityOS

Products and services

  • EMA Platform (Embryology Management Assistant) End-to-end AI-powered embryo evaluation SaaS platform that connects the entire IVF care team through automated embryo grading, analytics, and communication tools, integrating with time-lapse incubators (Embryoscope, Geri) and EMR systems. Designed for IVF clinics and fertility centers seeking to standardize embryo selection, reduce evaluation time, and improve pregnancy rates.
  • AIVF Genetics Non-invasive AI tool that provides probabilistic euploidy estimates (0-99 score) for embryos using time-lapse imaging, integrating maternal age, embryo morphology scores, morphokinetic parameters, and Embryo Resilience data to support genetic-quality assessment without invasive PGT-A biopsy. Targeted at IVF clinics and reproductive medicine labs.
  • ART Compass Wholly-owned AIVF subsidiary product offering IVF lab management tools and a clinic operating system for quality assurance and laboratory workflow support, used by fertility clinics and embryology labs.
  • AIVF Mobile App Patient-facing mobile application that provides access to personal fertility health data processed by the clinic, remote journey monitoring, and scheduling features for patients undergoing IVF treatment.

Quantifiable outcome

  • 70% probability of success for embryos with high AIVF score
  • +4 more outcomes

Companies that use AiVF

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

AiVF technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature9 records

AiVF partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • American Hospital of ParisflagshipStrategic or Co-development Partner · 8 December 2025The American Hospital of Paris uses AIVF technology to analyze embryo development data, aiming to halve the number of IVF cycles needed to achieve pregnancy with 70% probability that recommended embryos will not have genetic abnormalities.
  • Genea BiomedxcoreTechnology or Integration · 18 May 2023Strategic partnership announced in May 2023 to integrate AIVF's AI-powered EMA platform with Genea Biomedx's Geri time-lapse incubator, expanding support for AI-powered embryo evaluation.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

AiVF competitors and assessment

Company assessment

Broad incumbents

  • Genea Biomedx: Genea Biomedx manufactures Geri time-lapse incubators and is AIVF's integration partner; as a major incubator OEM with R&D resources it represents both a channel and a potential competitor.
  • Vitrolife: Vitrolife is a global IVF media, device and genomics supplier whose Embryoscope time-lapse incubator platform is integrated with AIVF; as a broad incumbent it could build or bundle competing AI embryo scoring.
  • CooperSurgical: CooperSurgical is a large incumbent in fertility and reproductive medicine spanning devices, genomics (PGT-A) and lab services, with overlapping AI-adjacent capabilities and the distribution to challenge AIVF in clinics.
  • FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific is a leading supplier of IVF media, devices and digital tools to fertility clinics, representing a broad incumbent whose scale and customer relationships compete with AIVF's clinic OS.
  • Hamilton Thorne: Hamilton Thorne provides ART/IVF instruments and clinical devices globally; its installed base of laser systems and imaging hardware gives it a platform adjacent to AIVF's AI evaluation layer.

Direct peers

  • Alife Health: Alife Health applies AI to IVF clinical decision support and embryo selection, directly competing with AIVF's EMA platform for the same fertility clinic customers with similar AI-on-time-lapse-imaging workflows.
  • Fairtility: Fairtility offers AI-based embryo assessment and decision-support tools for IVF clinics, competing head-to-head with AIVF in automating embryo grading and ranking using time-lapse incubator data.
  • Univfy: Univfy provides AI-based IVF success prediction and patient counseling tools to fertility clinics, directly competing with AIVF's analytics and decision-support positioning.

Emerging players

  • Embryonics: Embryonics develops AI-powered embryo viability prediction for IVF, an emerging niche player overlapping with AIVF's Day-3/Day-5 evaluation offerings.

Others

  • Progyny: Progyny is a leading fertility benefits management platform that influences which clinics and tools patients use; it is an adjacent ecosystem player whose provider selection decisions can drive or constrain AIVF clinic adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

AiVF social profiles

Digital presence

AiVF compliance and trust

Trust signal

Compliance6 records

AiVF financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AiVF leadership team

Management profile

Number of profiles

Profiles10 records

AiVF subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

AiVF funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AiVF M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AiVF

What does AiVF do?

AIVF develops and sells the EMA (Embryology Management Assistant) platform — an AI-powered clinical decision-support SaaS for IVF clinics that performs automated, deep-learning-based embryo evaluation (Day-3 and Day-5), non-invasive euploidy prediction via AIVF Genetics, and clinic-wide analytics and messaging, integrating with time-lapse incubators (Embryoscope, Geri) and EMR systems. The company also offers ART Compass (lab management) and a patient mobile app as adjacent products to its core IVF clinic software.

Is AiVF a public or private company?

AiVF is a private company. It is classified as venture growth investor backed and is currently operating.

When was AiVF founded?

AiVF was founded in 2018. It employs 11 to 50 people.

Where is AiVF based?

AiVF is headquartered in Tel Aviv, Israel, in the Middle East region.

How does AiVF make money?

One revenue line is on record: saaS Platform Subscription.

Who are AiVF's main competitors?

Broad incumbents on record are Genea Biomedx, Vitrolife, CooperSurgical, FUJIFILM Irvine Scientific and Hamilton Thorne. Direct peers are Alife Health, Fairtility and Univfy. Embryonics is listed as an emerging player. Progyny is listed as an others.

Does AiVF have an API?

No public API is recorded for AiVF.

What industry is AiVF in?

AiVF's product category is Clinical decision-support software for IVF / reproductive medicine. Its primary akta.pro industry code is BPAEAHAF, AI/ML Engineering & Model Development Services. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Digital JournalAI tools help choose best embryos for IVFAI tools are increasingly being used to help select embryos with the best chance of successful implantation during IVF procedures, with the American Hospital of Paris using technology from Israeli start-up AIVF to analyze embryo development data. The hospital, which performs over 2,300 IVF procedures annually, aims to halve the number of cycles needed to achieve pregnancy, with AIVF offering a 70-percent probability that recommended embryos will not have genetic abnormalities. Bioethicists, however, have urged caution and argue patients should be informed about and given the option to opt out of AI-assisted embryo selection.PR NewswireAIVF Recognized Among Top 50 Most Promising Digital Health Startups by CB InsightsAIVF was named one of the top 50 most promising digital health startups by CB Insights. Its AI platform EMATM operates in 35 clinics across 14 countries, aiming to improve IVF success rates. The company continues to advance fertility technology as demand grows globally.PR NewswireAIVF Expands Launching the First AI-Powered IVF Solution at the Perfetto Clinic in Goiânia, BrazilAIVF launched the first AI-powered IVF operating system at Perfetto Clinic in Goiânia, Brazil. This expansion addresses the growing demand for assisted reproductive technologies in Brazil, where registered clinics increased by 63% and frozen embryos tripled between 2013 and 2019.PR NewswireAIVF se expande mediante el lanzamiento de la primera solución FIV impulsada por IA en la clínica Perfetto en Goiânia, BrasilAIVF, a reproductive technology company, launched its AI-powered EMA™ IVF operating system at Perfetto clinic in Goiânia, Brazil, marking the first AI-powered IVF solution deployment in Latin America. The system offers 38% higher precision in embryo evaluation compared to embryologists working alone, with embryos scoring high on EMA™ showing a 70% probability of achieving a successful pregnancy. The expansion addresses Brazil's rapidly growing assisted reproduction market, where the number of registered clinics rose 63% from 2013 to 2019 and frozen embryos tripled.PR NewswireAIVF expande o lançamento da primeira solução de fertilização in vitro alimentada por IA naclínica Perfetto, em Goiânia, BrasilAIVF, a reproductive technology company, launched its AI-powered IVF operating system EMA™ in Brazil at the Perfetto multidisciplinary fertility clinic in Goiânia, marking the first deployment of the system in Latin America. The EMA™ platform, developed using large and diverse datasets from leading institutions in the United States, Europe, and Asia, improves clinical decision-making, streamlines operations, and strengthens clinic-patient communications. The system's embryo assessment module demonstrated 38% higher precision compared to embryologists alone, with high-scoring embryos showing a 70% probability of successful pregnancy.PR NewswireAIVF and Genea Biomedx enter a partnership to jolt the $50B IVF Market.AIVF and Genea Biomedx launched an integrated IVF system combining AIVF's AI platform with Genea's Geri incubator. The partnership claims to increase pregnancy rates by 48% and give physicians 40% more time. The solution is now available for Genea's Geri incubator.PR NewswireAIVF and Genea Biomedx enter a partnership to jolt the $50B IVF Market.AIVF and Genea Biomedx launched an integrated IVF system combining AIVF's EMA AI platform with Genea's Geri incubator. The partnership aims to increase clinic efficiency and success rates, reducing patient costs and generating greater revenues.PR NewswireAIVF and Genea Biomedx enter a partnership to jolt the $50B IVF Market.AIVF and Genea Biomedx announced an integrated IVF system combining AIVF's EMA AI platform with Genea's Geri incubator. The partnership aims to increase IVF clinic efficiency and success rates, with AIVF's platform reported to raise pregnancy rates by 48% and give physicians 40% more time.PR NewswireRubenstein Public Relations Retained by Reproductive Technology Company, AIVF, as Agency of RecordAIVF, a Tel Aviv-based reproductive technology company founded in 2018, has retained Rubenstein Public Relations as its agency of record to broaden awareness of its AI-powered fertility solutions that help clinics optimize IVF processes and outcomes. RPR, a New York-based communications agency, will support AIVF's media relations and outreach efforts as the fertility technology company seeks to expand its reach. The partnership aligns RPR's healthcare communications expertise with AIVF's mission to accelerate digital transformation in fertility care.